Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Abstract CT228: Concordance between tissue and circulating tumor DNA (ctDNA) testing for neurotrophic tyrosine receptor kinase (NTRK) gene fusions in larotrectinib (laro) clinical trials

Erin R. Rudzinski, Marc Ladanyi, Lauren L. Ritterhouse, Felix Sahm, Ricarda Norenberg, Hong Zheng, Chi Chen, Vadim Bernard-Gauthier, Nicoletta Brega, Cornelis M. van Tilburg, Jessica J. Lin, Marcia S. Brose, Ulrik N. Lassen, Ray McDermott, Theodore W. Laetsch, David S. Hong, Alexander Drilon, Sinchita Roy-Chowdhuri

Cancer Res (2023) 83 (8_Supplement): CT228.

https://doi.org/10.1158/1538-7445.AM2023-CT228

Published: 14 April 2023

View articletitled, Abstract CT228: Concordance between tissue and circulating tumor DNA (ctDNA) testing for neurotrophic tyrosine receptor kinase (NTRK) gene fusions in larotrectinib (laro) clinical trials

Journal Articles

Abstract CT545: Variability in NTRK gene fusions does not appear to impact response to larotrectinib

Marc Ladanyi, Sinchita Roy-Chowdhuri, Lauren Ritterhouse, Felix Sahm, Ricarda Norenberg, Kui Shen, Chi Chen, Marc Fellous, Nicoletta Brega, Cornelis M. van Tilburg, Jessica J. Lin, Marcia S. Brose, Ulrik N. Lassen, Ray McDermott, Theodore W. Laetsch, David S. Hong, Alexander Drilon, Erin R. Rudzinski

Cancer Res (2022) 82 (12_Supplement): CT545.

https://doi.org/10.1158/1538-7445.AM2022-CT545

Published: 15 June 2022

View articletitled, Abstract CT545: Variability in NTRK gene fusions does not appear to impact response to larotrectinib

Journal Articles

Abstract CT062: Efficacy and safety of larotrectinib in patients with cancer and NTRK gene fusions or other alterations

David S. Hong, Afshin Dowlati, Howard Burris, Edward Chu, Marcia S. Brose, Anna F. Farago, Cornelis M. van Tilburg, Shivaani Kummar, Leo Mascarenhas, John A. Reeves, Marion Rudolph, Patricia Maeda, Barrett H. Childs, Theodore W. Laetsch, Alexander Drilon

Cancer Res (2020) 80 (16_Supplement): CT062.

https://doi.org/10.1158/1538-7445.AM2020-CT062

Published: 15 August 2020

View articletitled, Abstract CT062: Efficacy and safety of larotrectinib in patients with cancer and NTRK gene fusions or other alterations

Journal Articles

Abstract CT043: Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced, RET-altered solid tumors

Vivek Subbiah, Matthew Taylor, Jessica Lin, Mimi Hu, Sai-Hong Ignatius Ou, Marcia S. Brose, Elena Garralda, Corinne Clifford, Michael Palmer, Erica Evans, Hongliang Shi, Beni Wolf, Justin F. Gainor

Cancer Res (2018) 78 (13_Supplement): CT043.

https://doi.org/10.1158/1538-7445.AM2018-CT043

Published: 01 July 2018

View articletitled, Abstract CT043: Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced, RET-altered solid tumors

Journal Articles

Abstract CT008: Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions

David S. Hong, Anna F. Farago, Marcia S. Brose, Howard A. Burris, Afshin Dowlati, Todd M. Bauer, Matthew Taylor, Alice T. Shaw, Adriana Estrada-Bernal, Anh T. Lee, Nisha Nanda, Michael C. Cox, Robert C. Doebele

Cancer Res (2016) 76 (14_Supplement): CT008.

https://doi.org/10.1158/1538-7445.AM2016-CT008

Published: 15 July 2016

View articletitled, Abstract CT008: Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions

Journal Articles

Abstract 4529: Pharmacokinetics (PK) of LOXO-101 during the first-in-human Phase I study in patients with advanced solid tumors: Interim update

Howard A. Burris, Alice T. Shaw, Todd M. Bauer, Anna F. Farago, Robert C. Doebele, Steven Smith, Nisha Nanda, Scott Cruickshank, Jennifer A. Low, Marcia S. Brose

Cancer Res (2015) 75 (15_Supplement): 4529.

https://doi.org/10.1158/1538-7445.AM2015-4529

Published: 01 August 2015

View articletitled, Abstract 4529: Pharmacokinetics (PK) of LOXO-101 during the first-in-human Phase I study in patients with advanced solid tumors: Interim update

Journal Articles

Abstract 1278: Phase 1 study of CS-7017, an oral PPAR-γ agonist, in combination with paclitaxel in advanced anaplastic thyroid cancer

Robert C. Smallridge, John A. Copland, Marcia S. Brose, J. Trad Wadsworth, Yariv Houvras, Keith C. Bible, Manisha H. Shah, Ann W. Gramza, Joshua P. Klopper, Reinhard von Roemeling

Cancer Res (2011) 71 (8_Supplement): 1278.

https://doi.org/10.1158/1538-7445.AM2011-1278

Published: 15 April 2011

View articletitled, Abstract 1278: Phase 1 study of CS-7017, an oral PPAR-γ agonist, in combination with paclitaxel in advanced anaplastic thyroid cancer

Journal Articles

Abstract 3840: Rap1 GTPase activating protein (Rap1GAP) is downregulated in DCIS and invasive ductal carcinoma

Sarah S. Rhee, Bora Lim, Hyoung-ha Kim, Yan Wang, Usman Aziz, Usman Butt, Waixing Tang, Lisa A. Vuchak, Angela DeMichele, Andrea B. Troxel, Michael D. Feldman, Judy L. Meinkoth, Marcia S. Brose

Cancer Res (2011) 71 (8_Supplement): 3840.

https://doi.org/10.1158/1538-7445.AM2011-3840

Published: 15 April 2011

View articletitled, Abstract 3840: Rap1 GTPase activating protein (Rap1GAP) is downregulated in DCIS and invasive ductal carcinoma

Journal Articles

Abstract 3254: Characterization of two mutant models with distinct expression profile of BRCA1 splice variant IRIS

Hyoung H. Kim, Mohammad U. Butt, Marcia S. Brose

Cancer Res (2010) 70 (8_Supplement): 3254.

https://doi.org/10.1158/1538-7445.AM10-3254

Published: 15 April 2010

View articletitled, Abstract 3254: Characterization of two mutant models with distinct expression profile of BRCA1 splice variant IRIS

Journal Articles

Molecular characterization of the role of PTK2/FAK amplification in oral squamous cell carcinoma (OSCC)

Kelly M. Quesnelle, Anthony M. Sparano, Yan Wang, Gregory S. Weinstein, Marcia S. Brose

Cancer Res (2006) 66 (8_Supplement): 798.

Published: 15 April 2006

View articletitled, Molecular characterization of the role of PTK2/FAK amplification in oral squamous cell carcinoma (OSCC)

Journal Articles

Unraveling oral squamous cell carcinoma using aCGH and expression profiling

Marcia S. Brose, Yan Wang, Michael Feldman, Gregory S. Weinstein, Kelly M. Quesnelle

Cancer Res (2006) 66 (8_Supplement): 37–38.

Published: 15 April 2006

View articletitled, Unraveling oral squamous cell carcinoma using aCGH and expression profiling

Journal Articles

Microarray anaylsis of Kat5 cells following targeting of BRAF with Bay 43-9006

Albert J. Sylvester, III, Madhu S. Kumar, Dawn K. Reichenbach, Marcia S. Brose

Cancer Res (2006) 66 (8_Supplement): 889.

Published: 15 April 2006

View articletitled, Microarray anaylsis of Kat5 cells following targeting of BRAF with Bay 43-9006

Journal Articles

Detection of BRAF hotspot mutations utilizing pyrosequencing

Cynthia S. Spittle, M. Renee Ward, Katharine Nathanson, Marcia S. Brose, Angelica Medina, Richard Letrero, Robin H. Edwards

Cancer Res (2006) 66 (8_Supplement): 48.

Published: 15 April 2006

View articletitled, Detection of BRAF hotspot mutations utilizing pyrosequencing

Journal Articles

Application of BRAF T1799A mutation screening in a thyroid nodule clinic

Kanchan Puttaswamy, May Lai, Zubair W. Baloch, Susan J. Mandel, Madhu S. Kumar, Akash Gupta, Virginia Livolsi, Ara Chalian, Marcia S. Brose

Cancer Res (2006) 66 (8_Supplement): 50.

Published: 15 April 2006

View articletitled, Application of BRAF T1799A mutation screening in a thyroid nodule clinic

Journal Articles

Characterization of head and neck squamous cell carcinoma using aCGH and expression profiling

Marcia S. Brose, Madhu S. Kumar, Kelly M. Quesnelle, Patricia Volpe, Duane Sewell, Michael Feldman, Barbara L. Weber

Cancer Res (2005) 65 (9_Supplement): 210.

Published: 01 May 2005

View articletitled, Characterization of head and neck squamous cell carcinoma using aCGH and expression profiling

Journal Articles

Genome-wide characterization of oral cavity squamous cell carcinoma using aCGH and expression profiling

Marcia S. Brose, Madhu S. Kumar, Patricia Volpe, Rebekah O’Donnell, Barry Ziober, Duane Sewell, Michael Feldman, Barbara L. Weber

Cancer Res (2004) 64 (7_Supplement): 1291.

Published: 01 April 2004

View articletitled, Genome-wide characterization of oral cavity squamous cell carcinoma using aCGH and expression profiling

Journal Articles

BRAF and NRAS mutations in subtypes of papillary thyroid cancer

Madhu S. Kumar, Zubair W. Baloch, Patricia Volpe, Virginia A. Livolsi, Marcia S. Brose

Cancer Res (2004) 64 (7_Supplement): 20–21.

Published: 01 April 2004

View articletitled, BRAF and NRAS mutations in subtypes of papillary thyroid cancer

Journal Articles

Constitutive Mitogen-activated Protein Kinase Activation in Melanoma Is Mediated by Both BRAF Mutations and Autocrine Growth Factor Stimulation

Kapaettu Satyamoorthy, Gang Li, Michelle R. Gerrero, Marcia S. Brose, Patricia Volpe, Barbara L. Weber, Patricia van Belle, David E. Elder, Meenhard Herlyn

Cancer Res (2003) 63 (4): 756–759.

Published: 15 February 2003

View articletitled, Constitutive Mitogen-activated Protein Kinase Activation in Melanoma Is Mediated by Both BRAF Mutations and Autocrine Growth Factor Stimulation

Journal Articles

BRAF and RAS Mutations in Human Lung Cancer and Melanoma

Cancer Res (2002) 62 (23): 6997–7000.

Published: 01 December 2002

View articletitled, BRAF and RAS Mutations in Human Lung Cancer and Melanoma

Update search

NARROW

Format

Journal

Article Type

Issue Section

Date

Availability

Abstract CT228: Concordance between tissue and circulating tumor DNA (ctDNA) testing for neurotrophic tyrosine receptor kinase (NTRK) gene fusions in larotrectinib (laro) clinical trials

Abstract CT545: Variability in NTRK gene fusions does not appear to impact response to larotrectinib

Abstract CT062: Efficacy and safety of larotrectinib in patients with cancer and NTRK gene fusions or other alterations

Abstract CT043: Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced, RET-altered solid tumors

Abstract CT008: Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions

Abstract 4529: Pharmacokinetics (PK) of LOXO-101 during the first-in-human Phase I study in patients with advanced solid tumors: Interim update

Abstract 1278: Phase 1 study of CS-7017, an oral PPAR-γ agonist, in combination with paclitaxel in advanced anaplastic thyroid cancer

Abstract 3840: Rap1 GTPase activating protein (Rap1GAP) is downregulated in DCIS and invasive ductal carcinoma

Abstract 3254: Characterization of two mutant models with distinct expression profile of BRCA1 splice variant IRIS

Molecular characterization of the role of PTK2/FAK amplification in oral squamous cell carcinoma (OSCC)

Unraveling oral squamous cell carcinoma using aCGH and expression profiling

Microarray anaylsis of Kat5 cells following targeting of BRAF with Bay 43-9006

Detection of BRAF hotspot mutations utilizing pyrosequencing

Application of BRAF T1799A mutation screening in a thyroid nodule clinic

Characterization of head and neck squamous cell carcinoma using aCGH and expression profiling

Genome-wide characterization of oral cavity squamous cell carcinoma using aCGH and expression profiling

BRAF and NRAS mutations in subtypes of papillary thyroid cancer

Constitutive Mitogen-activated Protein Kinase Activation in Melanoma Is Mediated by Both BRAF Mutations and Autocrine Growth Factor Stimulation

BRAF and RAS Mutations in Human Lung Cancer and Melanoma

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only